title: Dendritic cell therapy in advanced gastric cancer: a promising new hope?
abstract: Advanced gastric cancer carries a very poor prognosis when the tumor becomes unresectable. Even with the best currently available chemotherapy regimens the survival rate remains dismal. A recent breakthrough in the treatment paradigm has been the approval of trastuzumab, a monoclonal antibody, in HER2-positive metastatic gastric cancer. A large number of trials are underway using dendritic cells (DCs) in a number of human malignancies and do show a ray of hope in management of these patients. This review attempts to summarize tumor immunology and the current data regarding use of DCs in gastric cancer therapy.
authors.affiliation: Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi 221005, U.P., India.
authors.forename: Mallika
authors.initials: M
authors.lastname: Tewari
authors.forename: Shipra
authors.initials: S
authors.lastname: Sahai
authors.forename: Raghvendra R
authors.initials: RR
authors.lastname: Mishra
authors.forename: Sunit K
authors.initials: SK
authors.lastname: Shukla
authors.forename: Hari S
authors.initials: HS
authors.lastname: Shukla
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D013274:Stomach Neoplasms / Q000276:immunology / Q000628:therapy*; D019139:Tumor Escape / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines